

Balaxi Pharmaceuticals Limited

September 26, 2022

To

Listing Department,

National Stock Exchange of India Limited

Exchange Plaza, Plot No C-1, Block G, Bandra Kurla Complex,

Bandra (E), Mumbai - 400051

NSE Symbol: BALAXI

Subject: Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 regarding receipt of In – Principle approval from the Stock Exchange

Dear Sir/Madam,

With reference to the captioned subject, we wish to inform you that the Company has received In – Principle approval from National Stock Exchange of India Limited for issue of 24,500 Equity Shares of Rs. 10/- each and 10,75,500 Equity Shares of Rs. 10/- each to be allotted on conversion of warrants under preferential basis.

The above mentioned In – Principle approval is enclosed herewith and this intimation will also be hosted on the Company's website at www.balaxipharma.in.

This is for your information and records.

Yours Faithfully,

For **Balaxi Pharmaceuticals Limited**

Ashish Maheshwari

(Managing Director)

DIN: 01575984

Registered Office:

2nd Floor, Maps Towers, Plot No.409, Road No. 81, Jubilee Hills, Phase-III, Hyderabad, Telangana, India - 500096.

CIN: L25191TG1942PLC121598

Phone: +91 40 23555300 | Email: info@balaxi.in | Website: www.balaxipharma.in

(Formerly known as Balaxi Ventures Limited)

National Stock Exchange Of India Limited

Ref: NSE/LIST/32399

September 26, 2022

The Company Secretary
Balaxi Pharmaceuticals Limited
Plot No.409, H.No. 8-2-293 MAPS Towers,
3rd Floor Jubilee hills,
Hyderabad-500096.

Kind Attn: Ms. Shalini Chinta

Dear Madam,

Sub: In - Principle approval under Regulation 28(1) of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015

We are in receipt of your application regarding In-principle approval for issue of 24500 Equity shares of Rs. 10/- each and 1075500 Equity shares of Rs. 10/- each to be allotted on conversion of warrants to be issued under preferential basis in terms of Regulation 28(1) of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015. In this regard, the Exchange is pleased to grant in-principle approval for the said issue subject to the Company fulfilling the following conditions:

1. Filing the listing application at the earliest from the date of allotment.
2. Receipt of statutory and other approvals and compliance of guidelines/regulations issued by the statutory authorities including SEBI, RBI, MCA, etc.
3. Compliance with all the applicable guidelines, regulations, directions of the Exchange or any statutory authorities as on the date of listing application.
4. Compliance of all conditions as per the SEBI (LODR) Regulations, 2015 as on date of listing, Companies Act, 1956 / Companies Act, 2013 and other applicable laws.
5. Submissions of documents as may be required by NSE and payment of applicable fees.

Further, the company is advised to strengthen internal controls (to monitor trades being executed by the proposed allottees in the scrip of the company) before allotment of securities in order to avoid any non-compliances in respect of trades being executed by the allottees in contravention of provisions of Chapter V of SEBI (ICDR) Regulations.

“Kindly note, this Exchange letter should not be construed as approval under any other Act /Regulation/rule/bye laws (except as referred above) for which the Company may be required to obtain approval from other department(s) of the Exchange. The Company is requested to separately take up matter with the concerned departments for approval, if any.”

The Exchange reserves its right to withdraw its in-principle approval at a later stage if the information submitted to the Exchange is found to be incomplete/incorrect/misleading/false or in contravention of any Rules, Bye-laws and Regulations of the Exchange, SEBI (LODR) Regulations, 2015, Guidelines/ Regulations issued by statutory authorities, etc.

Yours faithfully,
For National Stock Exchange of India Limited

Jiten Patel
Manager

This Document is Digitally Signed

National Stock Exchange Of India Limited*Continuation*

Cc:

National Securities Depository Limited
4th Floor, Trade World
Kamala Mills Compound
Senapati Bapat Marg
Lower Parel, Mumbai 400 013.

Central Depository Services Limited
Marathon Futurex, A-Wing, 25th
floor, NM Joshi Marg, Lower Parel,
Mumbai-400013.

P.S. Checklist of all the further issues is available on website of the exchange at the following URL:
<https://www.nseindia.com/companies-listing/raising-capital-further-issues-main-sme-checklist>

This Document is Digitally Signed